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National strategy for serological diagnosis ofHIV infection
A. F. FLEMING, D. J. MARTIN, SUBCOMMITTEE OF THE AIDS ADVISORY GROUP
ON STRATEGIES FOR HIV TESTING*
TIe initial tests for serum antibodies to the humanimmunodeficiency virus type I (HIV-1), intro-duced in 1985, were enzyme-linked immuno-
sorbent assays (EUSAs) for which virallysates were the
source of antigens. These tests were not 100% sensitive
and, because of the presence of antigenic proteins derived
from the cells in which the viruses were cultured, biologi-
cal false-positive results were sometimes obtained, espe-
cially with sera from blacks from malaria- endemic areas,
sera from individuals with human leucocyte antigen anti-
bodies, or stored sera.,,2 This necessitated confirmatory
testing of all EUSA-positive sera by means of Western
blot (WE), radio-immunoprecipitation assay (RIPA) or
indirect immunofluorescent antibody assay.
Soon after the release of the first-generation tests,
second-generation tests were developed in which the
antigens were either (z) recombinanl, i.e. a portion of a
viral genome is inserted into a vehicle, e.g. a bacterium
or yeast, which is easily cultured and produces large
quantities of specific viral antigens; or (iz) synthetic, i.e.
they form peptide chains of 10 - 40 amino acids homo-
logous to a portion of a viral antigen. Tests based on
either recombinant or synthetic peptide antigens have
sensitivities and specificities higher than first-generation
tests; however, recombinant antigen tests may yield
some false-positives (lower specificity) due to cOntarni-
naRts from the vehicle, whereas the synthetic antigen
tests may lack some sensitivity. The techniques of
second-generation ELISA tests have been varied (e.g.
antigen and antibody capture, competitive, immuno-
globulin class-specific, and substrate amplification
assays) in order to improve sensitivity and specificity.
Other tests have used agglutination (gelatin panicles,
red cells, autologous red cells or latex particles), particle
adherence or dot-blot techniques, and are technically
simple, instrument-free and yield rapid results.
Combination assays have been designed to screen for
HIV-1, HIV-2, human T-celllymphotropic virus type I
(HTLV-I) and HTLV-II simultaneously. The generally
excellent specificity and sensitivity of commercially
available second-generation test kits have been evalu-
ated and reviewed several times; sensitivity should
approach 100% and specificity should be above 97%
with sera from both blacks and whites.3,.
In third-generation tests now available, recombinant
or synthetic peptide antigens have been incorporated
into antigen sandwich ELISAs, with funher gains in
sensitivity and specificity.' All classes of immunoglobu-
lin antibodies are detected, thereby allowing earlier
recognition of infections; the 'window' period berween
infection and seropositivity is shonened by an average of
5 days,' the median length of the window having been
estimated previously to be 2,1 months.-
The conventional method of anti-HIV testing has
been to apply a screening test of which all negative results
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were accepted but positive sera were retested by means of
a confirmatory test, usually WE. This procedure was dic-
tated by the low specificity of first-generation tests, and
the WE has the disadvantages of being expensive, techni-
cally complicated and difficult to interpret, especially in
sub-Saharan Africa.' It is no longer the gold standard,
being less sensitive for detection of early infections than
third-generation EUSAs.' Early experience in Zambia
and the UK showed that HIV testing could be simplified
through the application of a first EUSA for screening fol-
lowed by a second different EUSA for confirmation,"'o
the laner replacing \X'B. The rwo tests should be based
on different principles (e.g. indirect and competitive
EUSAs) and have different sources of antigen (e.g. viral-
lysate and synthetic peptide). The first test should have
high sensitivity, be technically simple and inexpensive;
the second test should have high specificity. Only the few
sera giving discrepant or indeterminate results need to be
referred for WE or RIPA, resulting in very considerable
savings in costs. It has been shown consistently in 14
published series of over 35 000 sera tested, that algo-
rithms based on many pairs of second-generation tests
yield results identical or nearly identical to those obtained
from the conventional algorithm, but at only one-third to
one-tenth the cost for reagents. 1'·22
Based on this large body of data, the Global Pro-
gramme on AIDS of the World Health Organisation has
recommended that three testing strategies be applied
according to the objective of testing (the safety of blood
or organ donation, surveillance or diagnosis) and the
prevalence of infection in the population. 23 The AIDS
Advisory Group of the Deparrment of National Health
and Population Development formed a subcomminee in
February 1992 to recommend national strategies for
HIV testing of sera in South Africa.
Objectives of HIV antibody testing
1. Safety ofblood transfusionJorgan donation. This
requires the screening of blood and blood products, and
of sera from donors of tissues, organs, sperm ova and
breast milk.
2. Surveillance. This requires unlinked and anony-
mous testing of sera for the purpose of monitoring the
prevalence of, and trends in, HIV infection over time in
a given population.
3. Diagnosis ofHIV infection. This entails volun-
tary testing of sera from (x) asymptomatic persons;
(ix) persons with clinical signs and symptoms suggestive
of HIV infection or AIDS; and (iix) persons in whom the
HIV antibody status is required for insurance, travel,
immigration or employment purposes. In these situa-
tions the requirements for these tests are not necessarily
endorsed; however it is recognised that requests for test-
ing will be made and testing will be carried our.
4. Research. Voluntary testing of serum from sub-
jects for epidemiological, clinical, virological or other
HIV-related studies.
Definitions
Sensitivity and specificity of antibody tests
A test with a high sensitivity will have few false-negative
results. Therefore, only tests of highest possible sensiti-
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FIG. 1.
Algorithm for donations of blood, organs and tissues.
should be based on different antigen preparations and/or
different test principles. Serum that is non-reactive on
the first test is considered HIV antibody-negative as is
serum that is reactive on the first test but non-reactive
on the second. Serum reactive on all three tests is con-
sidered HIV antibody-positive. Serum that is reactive on
the first and second tests bur non-reactive on the third




Donor traced and counselled.







Unlinked and anonymous RN antibody testing is per-
formed to assess the prevalence of HIV infection in a
population at a given rime and to monitor trends over
rime. Strategy IT is recommended in populations of low
prevalence ("" 10%) and strategy I in populations of
higher prevalence (> 10%) (Table I). At present in
South Africa, testing for the purpose of surveillance
should follow strategy IT. Strategy I will be adopted at a
later stage if seroprevalences increase above 10% and,
the PPV of a single test will therefore have increased to
an acceptable level (Fig. 3).
The donor found to be HIV antibody-positive will be
categorised as an asymptomatic or symptomatic patient
and will be referred for further diagnostic investigation
(Table I; Fig. 2). The blood transfusion service will
make a reasonable attempt to inform the donor of an
irregular result and will refer the donor for counselling
and confirmatory testing. In some instances the blood
transfusion service may wish to carry out a confirmatory
test for the benefit of the recipients of previous negative
donations.
Donations ofblood, organs and tissues
The purpose of HIV antibody testing is to ensure a safe
supply of blood/organs/tissues to the recipient. One test,
highly sensitive for antibodies to both HIV-l and HIV-2,
is the only requirement. Strategy I should be followed
(Table I; Fig. 1). In the event of a patient requiring a
transfusion of blood in an emergency situation, before
other tests can be carried out, the use of a rapid test is
endorsed.
Design of testing protocols
It is imponant that quality assurance procedures be
stringently complied with so as to maximise the accu-
racy of the laboratory results. Procedures for detecting
both laboratory and clerical errors must be included in
all protocols. The selection of appropriate tests will
depend on the testing site. At a primary health care level
tests not requiring specialised equipment (insrrument-
free tests) are endorsed. More sophisticated testing sys-
tems will be available at regional level, and highly spe-
cialised facilities at the reference laboratories.
Prevalence of Testing
Objective of testing infection strategy'
Safety of blood transfusions/ All prevalences
organ donations
Surveillance '" 10% 11
>10% I
Diagnosis
Clinical signs/symptoms All prevalences 11
of HIV infection/AIDS
Asymptomatic '" 10% III
>10% 11
"See text
vity should be used when· there is a need to minimise the
rate of false-negative results (e.g. in testing of blood/
organ donations). A test with a high specificity will have
few false-positive results and should be used when there
is a need to minimise the rate of false-positive results
(e.g. in diagnosis ofHIV infection).
Strategies for HIV antibody testing
The WHO recommends three testing strategies to maxi-
mise accuracy while minimising cost. Which strategy is
most appropriate will depend on the objective of the test
and the prevalence ofHIV in the population (Table I).
Strategy I. All sera are tested with one EUSA or
rapid/simple assay. Serum that is reactive is considered
RIV antibody-positive. Serum that is non-reactive is
considered HIV antibody-negative.
Strategy IT. All sera are tested first with one EUSA
or rapid/simple assay. Serum that is non-reactive on the
first test is considered RIV antibody-negative. Any
serum found reactive on the first assay is retested (or a
second sample from the same subject is tested) with a
second EUSA or rapid/simple assay based on a different
antigen preparation and/or different test principle (e.g.
indirect versus competitive EUSA). Serum that is reac-
tive on both tests is considere(l HIV antibody-positive.
Any serum that is reactive on the first test but non-
reactive on the second test is also considered antibody-
negative, but in some circumstances will be subject to
further tests.
Strategy ill. As in strategy IT, all sera are· tested first
with one EUSA or rapid/simple assay and any reactive
samples are retested with a different assay. Strategy ill,
however, requires a third test if serum is found reactive
on the second assay. The three tests in this strategy
TABLE!.
Recommendations for HIV testing strategies according to
test objective and prevalence of infection in the popUlation
Positive and negative predictive values
The probability that a test will accurately determine the
true infection status of an individual varies with the
prevalence of RIV infection in the population from
which the person comes. In general, the higher the
prevalence of HIV infection, the greater the probability
that a person who tests positive is truly infected. The
proponion of samples testing false-positive therefore
decreases with increasing prevalence (i.e. the greater the
positive predictive value [pPV]). Conversely, the likeli-
hood that a person with negative test results is truly
uninfected decreases as prevalence increases. Therefore,
as prevalence increases, so does the proportion of sam-
ples testing false-negative (i.e. the negative predictive
value [NPV]).
Equivocallborderline/indetenninate/doubtful
results are test results that are difficult to interpret.
Discrepant/discordant results refer to a situation
when a definite positive and negative result are obtained






1 Negative 11 Posjve 11 Equivocal 1-Repeat same sample
Further coUnS~ling:-i Positive I~ Further counselling
Second blood sample Test1-2nd blood sample
~ ~~__~'"fle" > 2 weeks
Test 2 I~-~
I IPositive 11 Negative 11 EqUil'>ea11
I I I •
INegative' IIjSitiVet 11 EqUivjl1 Reference
laboratory




Diagnosis: all symptomatic subjects and asymptomatic
subjects in populations where seroprevalence is > 10%
(strategy 11).
Tests designed to detect only anti-HIV-l may be
used for national surveillance for as long as HIV-2
prevalence remains low. It is recommended that tests
that detect antibodies to both HIV-l and HIV-2 be used
to monitor their spread in high-risk sentinel populations.
Whenever HIV-2 is found to be a growing problem,




Seroprevalence <10% Seroprevalence >10%
strategy 11 strategy I
r-----.---=:::.;__'-r-I:::;---.jr-----,I
I Equivocal' 11 Positive 11 Negative I
L--='_~ L-_.----_-' +
Recorded
Test 2 as such
·same serum _ i
===:~==== I Positive I~.




Accurate testing is also crucial in respect of HIV anti-
body testing for diagnostic purposes. HIV infection is a
fatal condition with a considerable impact on the
lifestyle of the infected individual, and still carries con-
siderable stigmatisation. Pre-test counselling must be
carried out. A second blood sample must be obtained from
all persons who react positively on the first test. The opponu-
nity to test a second sample will help eliminate any possible
laboratory or clerical errors. At the time the second sample is
obtained the patient should be offered funher counselling.
Strategy IT is recommended for testing all patients with
symptoms suggestive of HIV infection and all asymp-
tomatic patients drawn from populations where sero-
prevalence is greater than 10% (Fig. 2).
If the patient is not available to give a second sample,
the first sample should be subjected to a second test and
the results of both tests recorded: if the patient is seen at
a later date, the patient should not be informed that
he/she is infected until a second sample is collected,
tested and found positive. Whenever the first test is
positive and the second negative, a specimen error is the
likely explanation for the discrepant results. The patient
should be counselled again and retested. Should the
result of the first test be equivocal, it is recommended
that a further sample be collected after a minimum
period of 2 weeks. If the result remains equivocal, serum
should be submitted to a designated reference labora-
tory. Strategy ill is recommended for testing all asymp-
tomatic patients drawn from populations where sero-
prevalence is 10% or less (Fig. 2, foomote).
In South Africa it is anticipated that initial testing by
means of instrument-free and technically simple kits
could be perfonned at the primary health care level, and
the second and third tests at a district/regional labora-
tory_ Sera providing discrepant results could be sent to a
reference laboratory of which there should be between
six and eight designated to act in this capacity.
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